^(125)I-HPNS-TOC的生物学评价  

Biological evaluation of ^(125)I-HPNS-TOC

作　　者：邹瑞[1,2] 程光亮[1,2] 潘林宏[1,2] 孙俊杰[1,2] 

机构地区：[1]太和县人民医院 [2]蚌埠医学院核医学教研室

出　　处：《安徽医学》2009年第7期706-708,共3页Anhui Medical Journal

基　　金：安徽省教育厅自然科学基金(项目号:2006kj123c)

摘　　要：目的研究联接标记法制备的125I-HPNS-TOC与小细胞肺癌株NCI-H446的受体结合特性及其在小鼠体内的分布。方法125I-HPNS-TOC与NCI-H446进行受体分析,并进行昆明鼠体内分布实验。结果125I-HPNS-TOC与NCI-H446上的SSTR结合的具有高亲和力,在小鼠体内主要经消化系统和泌尿系统排出体外。结论125I-HPNS-TOC与SSTR结合力高,有望成为生长抑素受体阳性肿瘤的靶向放射性药物。Objective To investigate characteristic of bound to the receptor within NCI - H446 cell lines of 125I - HPNS - TOC, labeled with conjugation labeling techniques, and its biodistribution in mice. Methods 1251 - HPNS - TOC, radioligand, detected using radioligand binding assay with somatostatin receptor（SSTR） positive NCI -H446 cell lines. Its biodistribution in normal mice was analyzed. Re- sults ^125I - HPNS - TOC had high affinity to SSTR within NCI - H446 cell lines. It was excreted by gastrointestinal - liver and kidney. Conclusion ^125I - HPNS - TOC has high affinity to SSTR. Our experiment indicate that ^125I - HPNS - TOC is a promising radiotherapeutic for SSTR positive tumors.

关 键 词：125I-HPNS-TOC 生长抑素受体 靶向 放射性药物 

分 类 号：R817[医药卫生—影像医学与核医学]